Forty-eight cases of leiomyosarcoma of bone in Japan: A multicenter study from the Japanese musculoskeletal oncology group
Background Leiomyosarcoma of bone (LMSoB) is a rare malignant bone tumor. This multicenter retrospective study was conducted to investigate the diagnosis and the clinical outcome of primary LMSoB in Japan. Methods Forty‐eight patients (average age: 52 years [range 14–88 years]) with primary LMSoB wh...
Gespeichert in:
| Veröffentlicht in: | Journal of surgical oncology 2016-09, Vol.114 (4), p.495-500 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 500 |
|---|---|
| container_issue | 4 |
| container_start_page | 495 |
| container_title | Journal of surgical oncology |
| container_volume | 114 |
| creator | Mori, Tomoaki Nakayama, Robert Endo, Makoto Hiraga, Hiroaki Tomita, Masato Fukase, Naomasa Kobayashi, Eisuke Kawai, Akira Ueda, Takafumi Morioka, Hideo |
| description | Background
Leiomyosarcoma of bone (LMSoB) is a rare malignant bone tumor. This multicenter retrospective study was conducted to investigate the diagnosis and the clinical outcome of primary LMSoB in Japan.
Methods
Forty‐eight patients (average age: 52 years [range 14–88 years]) with primary LMSoB who were treated at registered institutes in Japan between 1991 and 2014 were recruited. The median follow‐up period was 44 months (range: 2–273).
Results
The 5‐year overall survival rates and disease‐free survival rates were 78.3% and 44.9%, respectively. Surgical treatment was performed in 42 patients, and R0 resection was achieved in 31 patients. Neoadjuvant chemotherapy was administered in 18 patients. The most common regimen (cisplatin‐based chemotherapy) was administered in 15 patients, however, no patient achieved a good response in both radiological and histological evaluations. The presence of metastasis at the first visit and a lack of definitive surgery were significantly correlated with poor overall survival, and the surgical margin was a significant prognostic factor for disease‐free survival.
Conclusions
This study is the largest LMSoB case series ever reported. Surgical treatment with wide margins was the only treatment that proved to be effective, whereas adjuvant chemotherapy in the present setting did not improve the overall survival. J. Surg. Oncol. 2016;114:495–500. © 2016 Wiley Periodicals, Inc. |
| doi_str_mv | 10.1002/jso.24322 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1815682834</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1815682834</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4932-eaf9e8c44a1d76263273fe8b7130e1d0c7d822d76c8000eb1e3e8f72f9dfc1453</originalsourceid><addsrcrecordid>eNpdkUtP3DAUha2qVRloF_0DlaVu2AT8msTuDo0YHkLQp4rYWB7nZsjgxIPtCMKvr4ehLLqwbPl85-rYB6FPlBxQQtjhKvoDJjhjb9CEElUWiij5Fk2yxgpRKbKDdmNcEUKUKsV7tMMqTvISE_Q09yGNBbTL24StiRCxb7CD1nejjyZY35nNzcL3gNsen5u16b_iI9wNLrUW-gQBxzTUI26C73C6hS0DETIT7eB8vAMHyTjse-udX454Gfyw_oDeNcZF-Piy76Hf8-Nfs9Pi4urkbHZ0UVihOCvANAqkFcLQuipZyXPwBuSiopwArYmtaslYlqzMD4QFBQ6yqVij6sZSMeV7aH87dx38_QAx6a6NFpzLIf0QNZV0Wkomucjol__QlR9Cn9NtKFFKyZTK1OcXalh0UOt1aDsTRv3vVzNwuAUeWgfjq06J3tSlc136uS59_vPq-ZAdxdbRxgSPrw4T7nRZ8Wqq_1ye6G_XPy7Z95tSz_lfqfKXdw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1814688299</pqid></control><display><type>article</type><title>Forty-eight cases of leiomyosarcoma of bone in Japan: A multicenter study from the Japanese musculoskeletal oncology group</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Mori, Tomoaki ; Nakayama, Robert ; Endo, Makoto ; Hiraga, Hiroaki ; Tomita, Masato ; Fukase, Naomasa ; Kobayashi, Eisuke ; Kawai, Akira ; Ueda, Takafumi ; Morioka, Hideo</creator><creatorcontrib>Mori, Tomoaki ; Nakayama, Robert ; Endo, Makoto ; Hiraga, Hiroaki ; Tomita, Masato ; Fukase, Naomasa ; Kobayashi, Eisuke ; Kawai, Akira ; Ueda, Takafumi ; Morioka, Hideo</creatorcontrib><description>Background
Leiomyosarcoma of bone (LMSoB) is a rare malignant bone tumor. This multicenter retrospective study was conducted to investigate the diagnosis and the clinical outcome of primary LMSoB in Japan.
Methods
Forty‐eight patients (average age: 52 years [range 14–88 years]) with primary LMSoB who were treated at registered institutes in Japan between 1991 and 2014 were recruited. The median follow‐up period was 44 months (range: 2–273).
Results
The 5‐year overall survival rates and disease‐free survival rates were 78.3% and 44.9%, respectively. Surgical treatment was performed in 42 patients, and R0 resection was achieved in 31 patients. Neoadjuvant chemotherapy was administered in 18 patients. The most common regimen (cisplatin‐based chemotherapy) was administered in 15 patients, however, no patient achieved a good response in both radiological and histological evaluations. The presence of metastasis at the first visit and a lack of definitive surgery were significantly correlated with poor overall survival, and the surgical margin was a significant prognostic factor for disease‐free survival.
Conclusions
This study is the largest LMSoB case series ever reported. Surgical treatment with wide margins was the only treatment that proved to be effective, whereas adjuvant chemotherapy in the present setting did not improve the overall survival. J. Surg. Oncol. 2016;114:495–500. © 2016 Wiley Periodicals, Inc.</description><identifier>ISSN: 0022-4790</identifier><identifier>EISSN: 1096-9098</identifier><identifier>DOI: 10.1002/jso.24322</identifier><identifier>PMID: 27302734</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Bone Neoplasms - mortality ; Bone Neoplasms - pathology ; Bone Neoplasms - therapy ; chemotherapy ; Chemotherapy, Adjuvant ; cisplatin ; Female ; Humans ; Leiomyosarcoma - mortality ; Leiomyosarcoma - pathology ; Leiomyosarcoma - therapy ; leiomyosarcoma of bone ; Male ; Middle Aged ; Prognosis ; prognostic factors ; Retrospective Studies ; surgery</subject><ispartof>Journal of surgical oncology, 2016-09, Vol.114 (4), p.495-500</ispartof><rights>2016 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4932-eaf9e8c44a1d76263273fe8b7130e1d0c7d822d76c8000eb1e3e8f72f9dfc1453</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjso.24322$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjso.24322$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27302734$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mori, Tomoaki</creatorcontrib><creatorcontrib>Nakayama, Robert</creatorcontrib><creatorcontrib>Endo, Makoto</creatorcontrib><creatorcontrib>Hiraga, Hiroaki</creatorcontrib><creatorcontrib>Tomita, Masato</creatorcontrib><creatorcontrib>Fukase, Naomasa</creatorcontrib><creatorcontrib>Kobayashi, Eisuke</creatorcontrib><creatorcontrib>Kawai, Akira</creatorcontrib><creatorcontrib>Ueda, Takafumi</creatorcontrib><creatorcontrib>Morioka, Hideo</creatorcontrib><title>Forty-eight cases of leiomyosarcoma of bone in Japan: A multicenter study from the Japanese musculoskeletal oncology group</title><title>Journal of surgical oncology</title><addtitle>J. Surg. Oncol</addtitle><description>Background
Leiomyosarcoma of bone (LMSoB) is a rare malignant bone tumor. This multicenter retrospective study was conducted to investigate the diagnosis and the clinical outcome of primary LMSoB in Japan.
Methods
Forty‐eight patients (average age: 52 years [range 14–88 years]) with primary LMSoB who were treated at registered institutes in Japan between 1991 and 2014 were recruited. The median follow‐up period was 44 months (range: 2–273).
Results
The 5‐year overall survival rates and disease‐free survival rates were 78.3% and 44.9%, respectively. Surgical treatment was performed in 42 patients, and R0 resection was achieved in 31 patients. Neoadjuvant chemotherapy was administered in 18 patients. The most common regimen (cisplatin‐based chemotherapy) was administered in 15 patients, however, no patient achieved a good response in both radiological and histological evaluations. The presence of metastasis at the first visit and a lack of definitive surgery were significantly correlated with poor overall survival, and the surgical margin was a significant prognostic factor for disease‐free survival.
Conclusions
This study is the largest LMSoB case series ever reported. Surgical treatment with wide margins was the only treatment that proved to be effective, whereas adjuvant chemotherapy in the present setting did not improve the overall survival. J. Surg. Oncol. 2016;114:495–500. © 2016 Wiley Periodicals, Inc.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Bone Neoplasms - mortality</subject><subject>Bone Neoplasms - pathology</subject><subject>Bone Neoplasms - therapy</subject><subject>chemotherapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>cisplatin</subject><subject>Female</subject><subject>Humans</subject><subject>Leiomyosarcoma - mortality</subject><subject>Leiomyosarcoma - pathology</subject><subject>Leiomyosarcoma - therapy</subject><subject>leiomyosarcoma of bone</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Prognosis</subject><subject>prognostic factors</subject><subject>Retrospective Studies</subject><subject>surgery</subject><issn>0022-4790</issn><issn>1096-9098</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkUtP3DAUha2qVRloF_0DlaVu2AT8msTuDo0YHkLQp4rYWB7nZsjgxIPtCMKvr4ehLLqwbPl85-rYB6FPlBxQQtjhKvoDJjhjb9CEElUWiij5Fk2yxgpRKbKDdmNcEUKUKsV7tMMqTvISE_Q09yGNBbTL24StiRCxb7CD1nejjyZY35nNzcL3gNsen5u16b_iI9wNLrUW-gQBxzTUI26C73C6hS0DETIT7eB8vAMHyTjse-udX454Gfyw_oDeNcZF-Piy76Hf8-Nfs9Pi4urkbHZ0UVihOCvANAqkFcLQuipZyXPwBuSiopwArYmtaslYlqzMD4QFBQ6yqVij6sZSMeV7aH87dx38_QAx6a6NFpzLIf0QNZV0Wkomucjol__QlR9Cn9NtKFFKyZTK1OcXalh0UOt1aDsTRv3vVzNwuAUeWgfjq06J3tSlc136uS59_vPq-ZAdxdbRxgSPrw4T7nRZ8Wqq_1ye6G_XPy7Z95tSz_lfqfKXdw</recordid><startdate>20160915</startdate><enddate>20160915</enddate><creator>Mori, Tomoaki</creator><creator>Nakayama, Robert</creator><creator>Endo, Makoto</creator><creator>Hiraga, Hiroaki</creator><creator>Tomita, Masato</creator><creator>Fukase, Naomasa</creator><creator>Kobayashi, Eisuke</creator><creator>Kawai, Akira</creator><creator>Ueda, Takafumi</creator><creator>Morioka, Hideo</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20160915</creationdate><title>Forty-eight cases of leiomyosarcoma of bone in Japan: A multicenter study from the Japanese musculoskeletal oncology group</title><author>Mori, Tomoaki ; Nakayama, Robert ; Endo, Makoto ; Hiraga, Hiroaki ; Tomita, Masato ; Fukase, Naomasa ; Kobayashi, Eisuke ; Kawai, Akira ; Ueda, Takafumi ; Morioka, Hideo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4932-eaf9e8c44a1d76263273fe8b7130e1d0c7d822d76c8000eb1e3e8f72f9dfc1453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Bone Neoplasms - mortality</topic><topic>Bone Neoplasms - pathology</topic><topic>Bone Neoplasms - therapy</topic><topic>chemotherapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>cisplatin</topic><topic>Female</topic><topic>Humans</topic><topic>Leiomyosarcoma - mortality</topic><topic>Leiomyosarcoma - pathology</topic><topic>Leiomyosarcoma - therapy</topic><topic>leiomyosarcoma of bone</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Prognosis</topic><topic>prognostic factors</topic><topic>Retrospective Studies</topic><topic>surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mori, Tomoaki</creatorcontrib><creatorcontrib>Nakayama, Robert</creatorcontrib><creatorcontrib>Endo, Makoto</creatorcontrib><creatorcontrib>Hiraga, Hiroaki</creatorcontrib><creatorcontrib>Tomita, Masato</creatorcontrib><creatorcontrib>Fukase, Naomasa</creatorcontrib><creatorcontrib>Kobayashi, Eisuke</creatorcontrib><creatorcontrib>Kawai, Akira</creatorcontrib><creatorcontrib>Ueda, Takafumi</creatorcontrib><creatorcontrib>Morioka, Hideo</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mori, Tomoaki</au><au>Nakayama, Robert</au><au>Endo, Makoto</au><au>Hiraga, Hiroaki</au><au>Tomita, Masato</au><au>Fukase, Naomasa</au><au>Kobayashi, Eisuke</au><au>Kawai, Akira</au><au>Ueda, Takafumi</au><au>Morioka, Hideo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Forty-eight cases of leiomyosarcoma of bone in Japan: A multicenter study from the Japanese musculoskeletal oncology group</atitle><jtitle>Journal of surgical oncology</jtitle><addtitle>J. Surg. Oncol</addtitle><date>2016-09-15</date><risdate>2016</risdate><volume>114</volume><issue>4</issue><spage>495</spage><epage>500</epage><pages>495-500</pages><issn>0022-4790</issn><eissn>1096-9098</eissn><abstract>Background
Leiomyosarcoma of bone (LMSoB) is a rare malignant bone tumor. This multicenter retrospective study was conducted to investigate the diagnosis and the clinical outcome of primary LMSoB in Japan.
Methods
Forty‐eight patients (average age: 52 years [range 14–88 years]) with primary LMSoB who were treated at registered institutes in Japan between 1991 and 2014 were recruited. The median follow‐up period was 44 months (range: 2–273).
Results
The 5‐year overall survival rates and disease‐free survival rates were 78.3% and 44.9%, respectively. Surgical treatment was performed in 42 patients, and R0 resection was achieved in 31 patients. Neoadjuvant chemotherapy was administered in 18 patients. The most common regimen (cisplatin‐based chemotherapy) was administered in 15 patients, however, no patient achieved a good response in both radiological and histological evaluations. The presence of metastasis at the first visit and a lack of definitive surgery were significantly correlated with poor overall survival, and the surgical margin was a significant prognostic factor for disease‐free survival.
Conclusions
This study is the largest LMSoB case series ever reported. Surgical treatment with wide margins was the only treatment that proved to be effective, whereas adjuvant chemotherapy in the present setting did not improve the overall survival. J. Surg. Oncol. 2016;114:495–500. © 2016 Wiley Periodicals, Inc.</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>27302734</pmid><doi>10.1002/jso.24322</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-4790 |
| ispartof | Journal of surgical oncology, 2016-09, Vol.114 (4), p.495-500 |
| issn | 0022-4790 1096-9098 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1815682834 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Adolescent Adult Aged Aged, 80 and over Bone Neoplasms - mortality Bone Neoplasms - pathology Bone Neoplasms - therapy chemotherapy Chemotherapy, Adjuvant cisplatin Female Humans Leiomyosarcoma - mortality Leiomyosarcoma - pathology Leiomyosarcoma - therapy leiomyosarcoma of bone Male Middle Aged Prognosis prognostic factors Retrospective Studies surgery |
| title | Forty-eight cases of leiomyosarcoma of bone in Japan: A multicenter study from the Japanese musculoskeletal oncology group |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T16%3A27%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Forty-eight%20cases%20of%20leiomyosarcoma%20of%20bone%20in%20Japan:%20A%20multicenter%20study%20from%20the%20Japanese%20musculoskeletal%20oncology%20group&rft.jtitle=Journal%20of%20surgical%20oncology&rft.au=Mori,%20Tomoaki&rft.date=2016-09-15&rft.volume=114&rft.issue=4&rft.spage=495&rft.epage=500&rft.pages=495-500&rft.issn=0022-4790&rft.eissn=1096-9098&rft_id=info:doi/10.1002/jso.24322&rft_dat=%3Cproquest_pubme%3E1815682834%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1814688299&rft_id=info:pmid/27302734&rfr_iscdi=true |